ClinicalTrials.gg
RecruitingNCT07717892Updated Nov 6, 2026

Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)

A Phase 3 interventional study of Solriamfetol Dose A and Solriamfetol Dose B in ADHD, sponsored by Axsome Therapeutics, Inc.. Recruiting at 31 sites in United States. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Axsome Therapeutics, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Nov 6, 20267 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
468
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States — 98 open to participants now, 116 under way, 5 of them phase 3. Attention Deficit Disorder with Hyperactivity · United States.

Planned enrollment
36th of 706
468 · median 70
Started
2026
with 32 others
Phase 3
121 of 807
4 open now
Primary completion
2028-06
later than 81 of 115 live
Registered
795th of 807
by date

Among the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, this one is the 36th largest by planned enrollment of the 706 interventional ones that give a count, is one of 33 that started in 2026, is one of 121 in phase 3, reaches primary completion later than 81 of the 115 other live ones, and was the 795th registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

98 of the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States are open now. Recruiting first, the newest first:

92 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, or all of them as a file.
02

Study summary

This study is a Phase 3, multi-center, randomized, 6-week, double-blind, placebo-controlled, parallel-group trial to assess the efficacy and safety of solriamfetol in adolescents aged 12 to \<18 years with ADHD.

Read the detailed description

Eligible subjects are adolescents, 12 to \<18 years of age, with a primary diagnosis of ADHD based on criteria established by the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) criteria. Subjects will be randomized in a 1:1:1 ratio to receive solriamfetol dose A, solriamfetol dose B or placebo once daily for 6 weeks.

03

Conditions studied

  • ADHD

Keywords

  • Attention deficit hyperactivity disorder
  • ADHD
  • Sunosi
  • Solriamfetol
  • Axsome
  • Non-stimulant therapy
  • Dopamine norepinephrine reuptake inhibitor
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, aged 12 to \<18 years.
  • Primary diagnosis of ADHD according to criteria.
  • Has parents/legal guardians provide written and has child provide written informed assent to participate in the study before the conduct of any study procedures.

Exclusion criteria

Exclusion Criteria:

  • Unable to comply with study procedures.
  • Medically inappropriate for study participation in the opinion of the investigator.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
468 participants (estimated)

Study arms

  • Experimental
    Solriamfetol Dose A

    Up to 6 weeks

    Drug: Solriamfetol Dose A

  • Experimental
    Solriamfetol Dose B

    Up to 6 weeks

    Drug: Solriamfetol Dose B

  • Placebo comparator
    Placebo

    Up to weeks

    Drug: Placebo

Interventions

  • DrugSolriamfetol Dose A

    Solriamfetol capsules, taken once daily

  • DrugSolriamfetol Dose B

    Solriamfetol capsules, taken once daily

  • DrugPlacebo

    Placebo capsules, taken once daily

06

What researchers measure

Primary outcomes

  1. ADHD-RS-5 Total Score, Change from Baseline to Week 6

    Attention Deficit/ Hyperactivity Disorder Rating Scale-5, Interview with Informant, Adolescent Version (ADHD-RS-5)

    Time frame: 6 weeks

07

Study locations

31 of 31 sites recruiting
  • Clinical Research Site
    Dothan, Alabama 36303, United States
    Recruiting
  • Clinical Research Site
    Little Rock, Arkansas 72211, United States
    Recruiting
  • Clinical Research Site
    Anaheim, California 92805, United States
    Recruiting
  • Clinical Research Site
    Irvine, California 92604, United States
    Recruiting
  • Clinical Research Site
    Long Beach, California 90806, United States
    Recruiting
  • Clinical Research Site
    Los Angeles, California 90015, United States
    Recruiting
  • Clinical Research Site
    Walnut Creek, California 94596, United States
    Recruiting
  • Clinical Research Site
    Coral Gables, Florida 33146, United States
    Recruiting
  • Clinical Research Site
    Gainesville, Florida 32607, United States
    Recruiting
  • Clinical Research Site
    Jacksonville, Florida 32256, United States
    Recruiting
  • Clinical Research Site
    Maitland, Florida 32751, United States
    Recruiting
  • Clinical Research Site
    Orlando, Florida 32801, United States
    Recruiting
  • Clinical Research Site
    Orlando, Florida 32803, United States
    Recruiting
  • Clinical Research Site
    Atlanta, Georgia 30318, United States
    Recruiting
  • Clinical Research Site
    Bardstown, Kentucky 40004, United States
    Recruiting
  • Clinical Research Site
    Owensboro, Kentucky 42301, United States
    Recruiting
  • Clinical Research Site
    Springfield, Massachusetts 01103, United States
    Recruiting
  • Clinical Research Site
    Worcester, Massachusetts 01608, United States
    Recruiting
  • Clinical Research Site
    Jackson, Mississippi 39206, United States
    Recruiting
  • Clinical Research Site
    Las Vegas, Nevada 89128, United States
    Recruiting
  • Clinical Research Site
    Staten Island, New York 10314, United States
    Recruiting
  • Clinical Research Site
    Portland, Oregon 97210, United States
    Recruiting
  • Clinical Research Site
    North Charleston, South Carolina 29405, United States
    Recruiting
  • Clinical Research Site
    Memphis, Tennessee 38119, United States
    Recruiting
  • Clinical Research Site
    Austin, Texas 78759, United States
    Recruiting
  • Clinical Research Site
    Friendswood, Texas 77546, United States
    Recruiting
  • Clinical Research Site
    San Antonio, Texas 78229, United States
    Recruiting
  • Clinical Research Site
    Provo, Utah 84604, United States
    Recruiting
  • Clinical Research Site
    Fairfax, Virginia 22030, United States
    Recruiting
  • Clinical Research Site
    Petersburg, Virginia 23805, United States
    Recruiting
  • Clinical Research Site
    Everett, Washington 98201, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2028, 24 months after the start.

Of 66 industry-sponsored phase 3 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's planned 24 months is above that.

Counting every sponsor, half of 80 studies reached it within 14 months; a quarter within 7 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2026
First posted
Jul 21, 2026
StartActual
Jun 25, 2026
Primary completionEst.
Jun 30, 2028
CompletionEst.
Jun 30, 2028
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
7 sites added
Show 7 added (7 United States)
  • Clinical Research Site · Anaheim, United States
  • Clinical Research Site · Owensboro, United States
  • Clinical Research Site · Petersburg, United States
  • Clinical Research Site · Everett, United States
  • Clinical Research Site · Orlando, United States
  • Clinical Research Site · Portland, United States
  • Clinical Research Site · Fairfax, United States
across 2 updates, Oct 13, 2026 – Nov 6, 2026
Show all 2 updates
  1. Nov 6, 2026
    3 sites added
    Show 3 added (3 United States)
    • Clinical Research Site · Orlando, United States
    • Clinical Research Site · Portland, United States
    • Clinical Research Site · Fairfax, United States
    + 1 other change: verification date
  2. Oct 13, 2026
    4 sites added
    Show 4 added (4 United States)
    • Clinical Research Site · Anaheim, United States
    • Clinical Research Site · Owensboro, United States
    • Clinical Research Site · Petersburg, United States
    • Clinical Research Site · Everett, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07717892
Responsible party
Sponsor
First posted
Jul 21, 2026
Start date
Jun 25, 2026
Primary completion
Jun 30, 2028 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Nov 6, 2026

Study contacts

Study Director
Contact
sol-adhd-304@axsome.com
212-332-5061

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion